GE HealthCare Technologies GEHC
Healthcare · Medical - Devices · Synthos Deep Dive · 2026-07-03
The Overview
GE HealthCare makes the big medical scanners you see in hospitals — MRI machines, CT scanners, ultrasound, X-ray — plus the contrast dyes patients get injected before a scan and the monitors that watch you in the ICU. It spun out of General Electric in early 2023 and is one of the two or three biggest names in the business worldwide.
Is the stock cheap or expensive? Cheap. You're paying about $13 for every $1 of next year's expected profit, which is inexpensive for a healthcare company. The catch is that the business grows slowly — sales creep up only about 5% a year — and the stock has actually fallen ~14% over the past year while the market went up 20%. So it's a bargain that hasn't worked yet.
Our verdict is Watch: a decent, sturdy company at a fair price, but with no growth spark and a chart that's still heading down. Not a mistake to own, but not a table-pounder either.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). Low-drama stock (it doesn't swing wildly) and the price is already cheap, which cushions the downside — but it carries a fair chunk of debt and its China/tariff exposure could bite.
- Growth Quality 5/10 (average). A steady, profitable business, but growing slowly and not especially high-margin. Solid, not exciting.
- Exponential Potential 3/10 (low). This is a big, mature company growing in single digits. Don't expect it to double quickly — that's not what this is.
The one big worry: a slowdown in China or new tariffs on medical equipment. Because the company only grows a few percent a year, there's little cushion — a demand air-pocket would hit both sales and the stock's valuation at once.
Important honesty note: unlike some of our deep dives, no outside expert in the Synthos knowledge base covers this stock. This call is built purely on the numbers and the chart — we say so plainly rather than manufacturing conviction we don't have.
Putting a number on it: our fair-value estimate is $75 against a current price of $71.72 — real upside if our numbers are right.
Our summary metrics
Cheap on earnings (13× FY26E) & low beta, but 2.4× net-debt/EBITDA, a −30% drawdown, and China/tariff cyclicality.
Only ~5% forward revenue / ~10% EPS CAGR; 42% gross, 7.5% net margin; steady but low-octane med-tech compounder.
Mature ~$21B-revenue imaging incumbent growing mid-single-digits and NOT accelerating — no multibagger runway.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature ~$21B-revenue imaging incumbent growing mid-single-digits and NOT accelerating — no multibagger runway.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $81 (high $91 / low $65; median $80; 10 Buy · 8 Hold · 0 Sell) — context, not our anchor |
| Valuation | 19.9× trailing EPS · 13.4× FY26E · 12.1× FY27E · 9.0× FY30E · EV/S 1.9× · EV/EBITDA 11.2× |
| Technicals | Downtrend — $65.57, −25.6% off 52-wk high, below 50/200-DMA, RSI 54, −13.7% 12-mo (SPY +20.6%, QQQ +30.3%) |
| Conviction | Low — 0 expert voices in the Synthos KB; verdict rests on fundamentals & quant only |
| Position sizing | Satellite-at-most, ~1–2% if bought; more of a value-watch than a conviction hold |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for GEHC — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $71.72, 6% above the 50-day average ($68), 2% below the 200-day average ($73) — a mixed trend. 19% below the 52-week high of $88, 21% above the 52-week low of $59.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $71.72 is currently inside the band (band $70–$76).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 53.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.40, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = GEHC · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
GE HealthCare (Nasdaq: GEHC) is a global medical-technology company spun out of General Electric on 2023-01-04, headquartered in Chicago and led by CEO Peter J. Arduini. It designs, manufactures, and services diagnostic imaging systems and related consumables, organized into four divisions: Imaging (MRI, CT, molecular imaging, image-guided therapy, X-ray, women's health), Ultrasound, Patient Care Solutions / PCS (monitoring, anesthesia, maternal-infant care), and Pharmaceutical Diagnostics / PDx (contrast media and radiopharmaceutical tracers). ~53,000 employees. Fiscal year ends December 31.
Revenue mix (FY2025, from FMP segmentation):
- By product segment: Imaging $9.25B · PCS $3.09B · PDx $2.90B. (FMP's FY25 segment file does not separately list the Ultrasound line; in FY23 Ultrasound was ~$3.46B. Total company FY25 revenue was $20.63B, so the segment file is partial — treat the mix as directional, with Imaging clearly the anchor.)
- By geography: United States $9.17B (44%) · China $2.03B (10%) · Other countries $9.43B (46%). The China line has been shrinking — $2.56B (FY23) → $2.14B (FY24) → $2.03B (FY25) — a real and ongoing headwind (see §11).
The core economics: a razor-and-blade model where a large installed base of scanners pulls through high-margin service contracts, software, and (in PDx) recurring contrast-agent consumables. It is a steady cash machine, not a growth rocket.
2. The expert thesis
There is no expert coverage of GEHC in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top array is empty. We will not cite conviction we do not have.
Accordingly, this verdict is fundamentals- and quant-driven only — built from the FMP financials, analyst estimates, valuation, technicals, and insider filings below. Where the LLY-style notes lean on a distilled expert panel, GEHC has none, and that absence is itself a data point: it caps our conviction at Low and is the main reason a cheap, sturdy name lands at Watch rather than Buy. If and when independent expert claims enter the KB, this note will be re-scored.
One quasi-signal that is traceable to primary filings (not opinion): a cluster of open-market insider purchases in May 2026 by multiple directors (see §9), which we treat as a mild positive, not a thesis.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Cheap (13× FY26E, 1.9× sales) and low-beta (0.86) cushion the downside, but net-debt/EBITDA 2.44×, a −30% max drawdown, and China/tariff cyclicality keep it out of the "safe" tier. |
| Growth Quality | 5 · Average | ~5% forward revenue CAGR and ~10% EPS CAGR, 42.5% gross / 7.5% net margin, ROE ~15% / ROIC ~7%. A dependable med-tech compounder — but low-octane and margin-light vs elite peers. |
| Exponential Potential | 3 · Low | A mature ~$21B-revenue incumbent growing mid-single-digits and decelerating slightly, not accelerating; no realistic path to a multibagger from a $30B cap in this category. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Imaging demand firms, PDx (contrast/tracers) keeps compounding, China stabilizes, tariffs ease. FY27E EPS beats to ~$5.60 (vs $5.40 cons); multiple re-rates toward the med-tech average ~17×. | ~$95 (+45%) |
| Base (our anchor) | Estimates roughly hit — FY26E EPS $4.88, FY27E $5.40; a steady ~10%-EPS grower earns a modest ~14× on FY27E. | ~$75 (+14%) |
| Bear | China worsens, tariffs bite hardware margins, capex-cycle air-pocket at hospitals. FY26E EPS misses to ~$4.60; multiple stays depressed ~11×. | ~$52 (−21%) |
Synthos fair value = the base case, ~$75 (+14%), with the full $52–$95 span as the honest range. This anchor sits below the Street's $81 consensus — we give less credit to a re-rating while growth stays mid-single-digit — and our base is essentially at the Street's $65 low target on the downside. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). GEHC is neither an exponential nor an elite compounder — it is a steady, mature incumbent:
- Forward growth: revenue CAGR FY25→FY30E ~4.9% ($20.63B → $26.20B); EPS CAGR ~9.9% ($4.56 → $7.30) as modest operating leverage and buyback help EPS outrun revenue.
- Acceleration (the 2nd derivative) is flat-to-slightly-negative: revenue growth was +4.8% (FY25) and consensus has it +5.7% (FY26E) → +4.7% (FY27E) → +4.7% (FY28E) → +6.1% (FY29E). No inflection — this is a mid-single-digit grower with no exponential curve. Per our flagship philosophy we pick forward next-exponentials over trailing compounders; GEHC is firmly a slow compounder, so it scores low here by design.
- Room to run: the global imaging/diagnostics TAM is large and durable, but GEHC is already a market leader — share gains are incremental, not a land-grab. At $29.8B the cap is not the constraint; the growth rate is. A 3× from here would require a category-changing catalyst (large-scale AI-imaging monetization, a transformational PDx franchise) that is not in the numbers today.
- Reinvestment runway: disciplined but modest — capex ~$0.48B/yr (2.5% of revenue), R&D ~6.5% of sales. Enough to defend the moat, not enough to bend the growth curve.
Exponential Potential: Low (3/10). Own GEHC, if at all, for a cheap, defensive, dividend-paying cash flow — not for a multibagger. That honest framing is why it belongs at most in a satellite/value sleeve, never the exponential tier.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $20.63B, +4.8% (FY24 $19.67B, +0.6% on FY23 $19.55B). Low-single-digit top line — dependable but slow.
- Quarterly trajectory: Q1'25 $4.78B → Q2 $5.01B → Q3 $5.14B → Q4 $4.67B → Q1'26 $5.13B (+7.4% YoY). Choppy but modestly higher; no acceleration signal.
- Margins: gross 42.5% TTM, EBITDA 17.0%, operating ~12.5%, net 7.5% TTM. Respectable for imaging hardware, but well below premium med-tech/pharma peers. Margin trend is roughly flat.
- Earnings: net income $2.08B FY25 (EPS $4.56, diluted $4.55) vs $1.99B / $4.37 FY24. Modest, steady growth. (Note: Q4'25 was optically soft — $184M net income on ~$478M of "other expenses" — but the FY figure is the clean read.)
- Cash flow: operating CF $1.99B, capex −$0.48B, FCF $1.51B FY25 (FCF yield ~5.1%). Consistent cash generation; FCF/OCF conversion ~75%.
- Balance sheet: total debt $10.0B, cash $4.51B, net debt $5.49B, net-debt/EBITDA 2.44× — moderate leverage, a legacy of the spin. Current ratio 1.17×, interest coverage 5.7×. Investment-grade and serviceable, but not a fortress. Goodwill + intangibles $14.6B (~46% of assets) — a reminder this is a carve-out with heavy purchase accounting.
6. Valuation — priced in or room?
On earnings, GEHC is inexpensive: 19.9× trailing EPS, and only 13.4× FY26E / 12.1× FY27E / 9.0× FY30E on consensus, with EV/S 1.9×, EV/EBITDA 11.2×, P/FCF ~19.6×. For a market-leading med-tech throwing off ~$1.5B FCF, those are undemanding multiples — the FMP letter rating is B (overall score 3/5), dinged mainly on debt-to-equity and P/E-vs-peers.
The honest problem is why it's cheap: ~5% revenue growth, a shrinking China line, tariff overhang, and a stock in a downtrend. The market is paying a low multiple because the growth is low — not an obvious mispricing so much as a fair price for a slow grower. The bull re-rating case (toward the ~16–18× med-tech average) needs a growth or margin catalyst that isn't yet visible.
Street targets (context): consensus $81, median $80, high $91, low $65 — 10 Buy / 8 Hold / 0 Sell. Our $75 base FV is below consensus because we don't underwrite a multiple re-rating without faster growth; note the Street low of $65 is essentially today's price, so even the bulls' floor implies limited downside. A fairly-priced steady compounder, not a deep-value screamer.
7. Technicals (from the tech block)
- Trend: down. $65.57 sits below the 50-DMA ($63.74) by a hair and well below the 200-DMA ($74.10), with the 50 under the 200 (death-cross posture). MACD +0.22 (marginally positive, off a low base).
- Location: −25.6% off the 52-week high ($88.16), +10.2% off the 52-week low ($59.49) — near the lower half of its range, with a max drawdown of −30.1% from peak. This has been a painful holding.
- Momentum: RSI(14) 54 — neutral, neither oversold nor overbought; no washed-out-bottom signal yet.
- Relative strength (the tell): GEHC −13.7% 12-mo vs SPY +20.6% and QQQ +30.3%; −8.9% 3-mo vs SPY +13.7% / QQQ +22.0%. Persistent, broad underperformance of both the market and the Nasdaq-100 it belongs to.
- Read: the chart does not confirm a bottom — GEHC is a laggard below both moving averages. A value-watcher waits for either a reclaim of the 200-DMA (~$74) on volume or a deeper flush toward the low-$50s before pressing. This is the single biggest reason the verdict is Watch, not Buy.
8. Moat & competitive position
GEHC's moat is a large global installed base of imaging systems that pulls through sticky, high-margin service, software, and consumables (contrast media and radiopharmaceutical tracers in PDx are genuinely recurring). Switching costs are real: hospitals standardize on a vendor's platform, workflows, and service network. The competitive frame is an oligopoly — GEHC vs Siemens Healthineers and Philips in imaging, with Canon and others regionally. Threats: pricing pressure in China (including domestic-champion policy favoring local vendors), hospital capex cyclicality, tariffs on cross-border medical equipment, and the slow pace of imaging replacement cycles.
Peer set (FMP-supplied, market cap): Agilent $36.9B, Alcon $34.0B, Cardinal Health $56.0B, Humana $47.6B, Insmed $24.2B, IQVIA $34.6B, Mettler-Toledo $26.4B, BeOne Medicines $31.8B, Koninklijke Philips $26.9B (the closest direct imaging comp), ResMed $30.4B. (FMP's peer list is a healthcare-cap-band basket, not a pure imaging comp set; Philips is the one true head-to-head — Siemens Healthineers, the other, isn't in the FMP list.) Against Philips, GEHC is larger, more profitable, and cheaper on earnings — but shares the same slow-growth, China-exposed profile.
9. Management, capital allocation & guidance
- Capital allocation: conservative and shareholder-returning at the margin — a small but growing dividend ($0.14/qtr, ~0.2% yield, payout ~4%), a $200M FY25 buyback (first meaningful repurchase since the spin), ~$0.48B capex, and gradual deleveraging (net-debt/EBITDA 2.44× vs 2.7× a year earlier). Appropriate for a mature cash generator; no empire-building.
- Insider activity (a mild positive, traceable to Form 4s): a cluster of open-market director PURCHASES in May 2026 — director Kevin Lobo bought 10,000 shares at $64.18 (2026-05-22), Rodney Hochman and Phoebe Yang Watkin also purchased in the low-$60s. Award-based grants to officers (Rackliffe, Culp) are routine comp, not signals, but the discretionary open-market buys near current prices are a constructive tell that insiders see value here.
- Management's own guidance: GEHC has no representation in the Synthos KB (management or otherwise), so we rely on the SEC-filed financials and FMP consensus rather than a distilled earnings-call track. Gap flagged: forward guidance detail (organic-growth and margin bridge) would come from the Q2'26 call on 2026-07-29 — not yet ingested.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $1.04, revenue ~$5.27B). Watch organic revenue growth, China, and book-to-bill / orders — the leading indicators for a mid-single-digit grower.
- China trajectory: the single most important swing factor — the line has fallen three years running; stabilization would materially help the bull case, further deterioration confirms the bear.
- Tariffs / trade policy: medical-equipment tariff exposure on a cross-border manufacturing base — a margin and demand risk to monitor.
- PDx franchise: contrast media and radiopharmaceutical tracers are the highest-quality recurring line — new-agent approvals and capacity would lift the mix.
- AI / software monetization: GEHC's imaging-AI and digital tools are the only credible path to bending the growth curve; evidence of real revenue would be re-rating fuel.
Thesis tripwires (what would change the call): reclaim of the 200-DMA (~$74) on strong orders would upgrade toward Buy; conversely, two more quarters of China decline plus tariff-driven margin compression would push toward Avoid.
11. Key risks
- China + tariffs (structural/cyclical): ~10% of revenue in a shrinking, policy-pressured China market, plus medical-equipment tariff exposure — on a base growing only ~5%, there's little cushion.
- Slow growth / no re-rating catalyst: the cheap multiple can stay cheap indefinitely if revenue stays mid-single-digit; this is a value trap risk, not a franchise risk.
- Leverage: net-debt/EBITDA 2.44× and a heavily intangible balance sheet (46% goodwill/intangibles) leave less room for a demand shock than the peers' fortresses.
- Hospital capex cyclicality: imaging is a big-ticket capital purchase; hospital budget tightening delays orders.
- Downtrend / relative weakness: the stock has lagged the market and QQQ badly for 12 months and sits below both moving averages — momentum is a real, present headwind.
- No expert coverage: the absence of any Synthos KB voice means lower confidence and no independent check on the fundamentals-only view.
12. Verdict, position sizing & monitoring
Watch. GEHC is a cheap (13× FY26E, 1.9× sales), cash-generative, market-leading imaging franchise with a helpful cluster of insider buying — but it grows revenue at only ~5%, carries moderate leverage and China/tariff exposure, has no expert coverage in the Synthos KB, and remains in a clear downtrend below both moving averages. That combination — fair value, low growth, weak chart, low conviction — is the textbook definition of a Watch: a name to track for either a growth reacceleration or a better entry, not to buy today on conviction.
- Sizing: if bought at all, satellite-only, ~1–2% as a cheap defensive holding — and preferably scaled in on a reclaim of the 200-DMA or a flush toward the low-$50s, not chased here.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-29). Upgrade path to Buy — Tactical requires stabilizing China + orders inflecting; downgrade path to Avoid requires continued China decline + margin compression.
- Single biggest risk: China + tariff pressure on a low-growth hardware base — a demand air-pocket would hit sales and the multiple at once, with no growth cushion to absorb it.
- This verdict is logged as a tracked Synthos call as of 2026-07-03 at $65.57.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — GEHC has no expert coverage in the Synthos knowledge base. This note is explicitly fundamentals- and quant-driven; no expert conviction is claimed or cited. Fabricated conviction is structurally impossible (claim-ID reconciliation), and here there simply are no claims to cite.
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Segmentation caveat: FMP's FY25 product-segment file omits the Ultrasound line and does not sum to total revenue; treat the segment mix as directional.
- Insider note: May-2026 director open-market purchases are traceable to SEC Form 4 filings and treated as a mild positive, not a thesis.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").